OpenAI Launches Stargate Community Plan to Offset Energy Costs and Support Local Power Infrastructure 
Sanofi Reports Positive Late-Stage Results for Amlitelimab in Eczema Treatment 
Intel Stock Slides Despite Earnings Beat as Weak Q1 Outlook Raises Concerns 
JPMorgan and Allen & Company Emerge as Big Winners in Warner Bros Discovery Bidding War 
Morgan Stanley Flags High Volatility Ahead for Tesla Stock on Robotaxi and AI Updates 
Netflix Stock Slips After Earnings as Soft 2026 Guidance Overshadows Subscriber Milestone 
Nintendo Stock Jumps as Switch 2 Becomes Best-Selling Console in the U.S. in 2025 
Valero Makes First Venezuelan Crude Purchase Under New U.S.-Caracas Deal 
Memory Chip Shortage Drives Higher Gadget Prices and Weakens Global Tech Demand 
Nvidia CEO Jensen Huang Plans China Visit Amid AI Chip Market Uncertainty 
Walmart to Cut PhonePe Stake in IPO as Tiger Global and Microsoft Exit 
FAA Says It Is Not Blocking Boeing 737 MAX 7 and MAX 10 Certification 
Elon Musk Shares Bold Vision for AI, Robots, and Space at Davos 
Microsoft Restores Microsoft 365 Services After Widespread Outage 
Trump Signs Executive Order to Limit Wall Street Investment in Single-Family Homes 
Tesla Plans FSD Subscription Price Hikes as Autonomous Capabilities Advance 
Court Allows Expert Testimony Linking Johnson & Johnson Talc Products to Ovarian Cancer 
ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) today announced that its house dust mite (HDM) sublingual allergy immunotherapy (SLIT) tablet, ACARIZAX®, has been approved in Canada.
The New Drug Submission (NDS) for ACARIZAX® was filed with Health Canada in May 2016. ACARIZAX® is indicated as allergy immunotherapy for the treatment of moderate to severe house dust mite-induced allergic rhinitis, with or without conjunctivitis, in adults 18 to 65 years of age confirmed by a positive skin prick test and/or in vitro testing for D. farinae or D. pteronyssinus IgE antibodies.
Henrik Jacobi, ALK’s Executive Vice President, Research and Development, said: “This new approval expands ALK’s SLIT-tablet range in Canada, which now covers grass, ragweed and, the most common of all respiratory allergies, house dust mite. We continue to develop our organisation and launch readiness in North America ahead of the introduction of the HDM SLIT-tablet.”
ACARIZAX® is currently approved in 18 countries worldwide and launched in nine. Registration reviews are underway in a further eight countries with further submissions planned.
ALK-Abelló A/S
For further information please contact:
Media: Jeppe Ilkjær, tel. +45 7877 4532, mobile +45 3050 2014
Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525
About ALK
ALK is a research-driven global pharmaceutical company focusing on allergy prevention, diagnosis and treatment. ALK is a world leader in allergy immunotherapy – a treatment of the underlying cause of allergy. The company has approximately 2,300 employees, with subsidiaries, production facilities and distributors worldwide. ALK has entered into partnership agreements with Torii, Abbott, and Seqirus to commercialise sublingual allergy immunotherapy tablets in Japan, Russia, and South-East Asia, and Australia and New Zealand, respectively. The company is headquartered in Hørsholm, Denmark, and listed on Nasdaq Copenhagen. Find more information at www.alk.net.
http://www.globenewswire.com/NewsRoom/AttachmentNg/36640687-4854-400a-b165-434b0e60920f
